Item 2.02 Results of Operations and Financial Condition.

On February 14, 2023, Sio Gene Therapies Inc. (the "Registrant") issued a press release announcing its financial results for the three and nine months ended December 31, 2022. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

    Exhibit
    Number                                       Description of Document

     99.1               Press Release of Sio Gene Therapies Inc., dated February 14, 2023, "Sio
                      Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results"

      104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses